Drug profile

The FDA adverse-event record for Ibr / Pi3 (Orig S-P Us) Lv

49 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Ibr / Pi3 (Orig S-P Us) Lv. See the species affected, top reactions, and outcomes below.

49
adverse-event reports
91.8%
death-coded share
Cattle
most-reported species
42
Death - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
49
Total Reports
45
Deaths Reported
91.8%
Death Rate

Active Ingredients

Ibr / Pi3 (Orig S-P Us) Lv

Administration Routes

NasalUnknownSubcutaneous

Species Affected

Cattle 49

Most Affected Breeds

Cattle (other) 23
Aberdeen Angus 11
Crossbred Bovine/Cattle 6
Charolais 2
Mixed (Cattle) 2
Red Angus 1
Holstein-Friesian also known as Holstein 1
Hereford cattle 1
Cattle (unknown) 1
Cattle (unspecified) 1

Most Reported Reactions

Death 42
Lack of efficacy - NOS 29
Respiratory signs 7
Lack of efficacy (bacteria) - NOS 7
Lameness 6
Death by euthanasia 5
INEFFECTIVE, ANTIBIOTIC 4
Lack of efficacy (endoparasite NOS) 4
Digestive tract disorder NOS 4
Other abnormal test result NOS 3
INEFFECTIVE, WEIGHT INC 3
Necropsy performed 3

Outcome Breakdown

Died
43 (38.1%)
Ongoing
28 (24.8%)
Recovered/Normal
20 (17.7%)
Outcome Unknown
14 (12.4%)
Euthanized
5 (4.4%)
Recovered with Sequela
3 (2.7%)

Ibr / Pi3 (Orig S-P Us) Lv Adverse Event Insights

49 reports name Ibr / Pi3 (Orig S-P Us) Lv; 45 recorded a death outcome (91.8% of reported events, not a population-level mortality rate). Active ingredient: Ibr / Pi3 (Orig S-P Us) Lv. Administration routes: Nasal, Unknown, Subcutaneous.

By species: Cattle (49 reports). By breed: Cattle (other) (23), Aberdeen Angus (11), Crossbred Bovine/Cattle (6).

Leading clinical signs: Death (42), Lack of efficacy - NOS (29), Respiratory signs (7), Lack of efficacy (bacteria) - NOS (7). Outcome, 113 coded reports: Died leads at 38.1%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.